INTERVENTION 1:	Intervention	0
Arm I (Omega-3 Fatty Acid)	Intervention	1
omega-3 fatty acid	CHEBI:25681	7-25
Patients receive omega-3 fatty acid PO daily for 7-14 days.	Intervention	2
omega-3 fatty acid	CHEBI:25681	17-35
omega-3 fatty acid: Given PO	Intervention	3
omega-3 fatty acid	CHEBI:25681	0-18
laboratory biomarker analysis: Correlative studies	Intervention	4
biomarker	CHEBI:59163	11-20
INTERVENTION 2:	Intervention	5
Arm II (Placebo)	Intervention	6
Patients receive placebo PO daily for 7-14 days.	Intervention	7
placebo: Given PO	Intervention	8
laboratory biomarker analysis: Correlative studies	Intervention	9
biomarker	CHEBI:59163	11-20
Inclusion Criteria:	Eligibility	0
Newly diagnosed stage I to III breast cancer and carcinoma in situ (including lobular carcinoma in situ [LCIS] and ductal carcinoma in situ [DCIS])	Eligibility	1
breast cancer	DOID:1612	31-44
carcinoma	HP:0030731,DOID:305	49-58
carcinoma	HP:0030731,DOID:305	86-95
carcinoma	HP:0030731,DOID:305	122-131
lobular carcinoma in situ	HP:0030076,DOID:3010	78-103
ductal carcinoma in situ	HP:0030075,DOID:0060074	115-139
Breast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day of enrollment	Eligibility	2
breast	UBERON:0000310	0-6
surgery	OAE:0000067	7-14
day	UO:0000033	68-71
day	UO:0000033	82-85
Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved written informed consent document	Eligibility	3
document	IAO:0000310	120-128
Tumor measures at least 1 centimeter on imaging or physical exam	Eligibility	4
centimeter	UO:0000015	26-36
Exclusion Criteria:	Eligibility	5
Any patient with surgery scheduled < 7days after biopsy	Eligibility	6
patient	HADO:0000008,OAE:0001817	4-11
surgery	OAE:0000067	17-24
Patients who are unable to refrain from the use of any NSAID or full-dose acetylsalicylic acid (ASA)-containing NSAID while taking study drug	Eligibility	7
acetylsalicylic acid	CHEBI:15365	74-94
drug	CHEBI:23888	137-141
Patients who will receive neoadjuvant chemotherapy are not eligible	Eligibility	8
Patients who are currently taking omega-3 fatty acids, as they are unable to be randomized to placebo	Eligibility	9
Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment	Eligibility	10
omega-3 fatty acid	CHEBI:25681	35-53
month	UO:0000035	63-68
Patients with an allergy or known hypersensitivity to fish	Eligibility	11
allergy	HP:0012393	17-24
hypersensitivity	GO:0002524,DOID:1205	34-50
Outcome Measurement:	Results	0
PUFA Levels in Normal and Metastatic Breast Tissue	Results	1
breast	UBERON:0000310	37-43
tissue	UBERON:0000479	44-50
Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3	Results	2
breast	UBERON:0000310	148-154
tissue	UBERON:0000479	155-161
blood	UBERON:0000178	255-260
Time frame: At time of surgery	Results	3
time	PATO:0000165	0-4
time	PATO:0000165	15-19
surgery	OAE:0000067	23-30
Results 1:	Results	4
Arm/Group Title: Arm I (Omega-3 Fatty Acid)	Results	5
omega-3 fatty acid	CHEBI:25681	24-42
Arm/Group Description: Patients receive omega-3 fatty acid PO daily for 7-14 days.	Results	6
omega-3 fatty acid	CHEBI:25681	40-58
omega-3 fatty acid: Given PO	Results	7
omega-3 fatty acid	CHEBI:25681	0-18
laboratory biomarker analysis: Correlative studies	Results	8
biomarker	CHEBI:59163	11-20
Overall Number of Participants Analyzed: 22	Results	9
Mean (Standard Deviation)	Results	10
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: ug/ml  Normal breast tissue 18:2 n-6: 22 participants	Results	11
breast	UBERON:0000310	31-37
tissue	UBERON:0000479	38-44
60.986         (40.392)	Results	12
Normal breast tissue 18:3 n-3: 22 participants	Results	13
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.232         (2.289)	Results	14
Normal breast tissue 20:2 n-6: 22 participants	Results	15
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
1.104         (0.96)	Results	16
Normal breast tissue 20:4 n-6: 22 participants	Results	17
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
2.221         (1.349)	Results	18
Normal breast tissue 20:3 n-3: 22 participants	Results	19
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.049         (0.107)	Results	20
Normal breast tissue 20:5 n-3: 22 participants	Results	21
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.027         (0.128)	Results	22
Normal breast tissue 22:6 n-3: 22 participants	Results	23
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.095         (0.443)	Results	24
Normal breast tissue n-3: 22 participants	Results	25
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.402         (2.572)	Results	26
Normal breast tissue n-6: 22 participants	Results	27
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.421         (2.085)	Results	28
Normal breast tissue n3/n-6 ratio: 21 participants	Results	29
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
ratio	UO:0000190	28-33
0.948         (0.468)	Results	30
Malignant breast tissue 18:2 n-6: 22 participants	Results	31
breast	UBERON:0000310	10-16
tissue	UBERON:0000479	17-23
44.137         (44.544)	Results	32
Malignant breast 18:3 n-3: 22 participants	Results	33
breast	UBERON:0000310	10-16
1.943         (2.162)	Results	34
Malignant breast 20:2 n-6: 22 participants	Results	35
breast	UBERON:0000310	10-16
0.889         (0.886)	Results	36
Malignant breast 20:4 n-6: 22 participants	Results	37
breast	UBERON:0000310	10-16
3.208         (1.948)	Results	38
Malignant breast 20:3 n-3: 22 participants	Results	39
breast	UBERON:0000310	10-16
0.034         (0.087)	Results	40
Malignant breast 20:5 n-3: 22 participants	Results	41
breast	UBERON:0000310	10-16
0.2         (0.665)	Results	42
Malignant breast 22:6 n-3: 22 participants	Results	43
breast	UBERON:0000310	10-16
0         (0)	Results	44
Malignant breast n-3: 22 participants	Results	45
breast	UBERON:0000310	10-16
2.178         (2.41)	Results	46
Malignant breast n-6: 22 participants	Results	47
breast	UBERON:0000310	10-16
48.233         (46.105)	Results	48
Malignant breast n-3/n-6 ratio: 22 participants	Results	49
breast	UBERON:0000310	10-16
ratio	UO:0000190	25-30
0.029         (0.031)	Results	50
Differences in PUFA level 18:2 n-6: 22 participants	Results	51
-16.85         (51.043)	Results	52
Differences in PUFA level 18:3 n-3: 22 participants	Results	53
-1.289         (2.784)	Results	54
Differences in PUFA level 20:2 n-6: 22 participants	Results	55
-0.215         (0.866)	Results	56
Differences in PUFA level 20:4 n-6: 22 participants	Results	57
0.986         (1.595)	Results	58
Differences in PUFA level 20:3 n-3: 22 participants	Results	59
-0.015         (0.105)	Results	60
Differences in PUFA level 20:5 n-3: 22 participants	Results	61
0.173         (0.545)	Results	62
Differences in PUFA level 22:6 n-3: 22 participants	Results	63
-0.095         (0.443)	Results	64
Difference in PUFA level n-3: 22 participants	Results	65
-1.224         (2.794)	Results	66
Difference in PUFA level in n-6: 22 participants	Results	67
44.812         (45.463)	Results	68
Difference in n-3/n-6 ratio: 21 participants	Results	69
ratio	UO:0000190	22-27
-0.92         (0.45)	Results	70
Results 2:	Results	71
Arm/Group Title: Arm II (Placebo)	Results	72
Arm/Group Description: Patients receive placebo PO daily for 7-14 days.	Results	73
placebo: Given PO	Results	74
laboratory biomarker analysis: Correlative studies	Results	75
biomarker	CHEBI:59163	11-20
Overall Number of Participants Analyzed: 19	Results	76
Mean (Standard Deviation)	Results	77
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: ug/ml  Normal breast tissue 18:2 n-6: 19 participants	Results	78
breast	UBERON:0000310	31-37
tissue	UBERON:0000479	38-44
72.762         (50.742)	Results	79
Normal breast tissue 18:3 n-3: 19 participants	Results	80
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.505         (2.041)	Results	81
Normal breast tissue 20:2 n-6: 19 participants	Results	82
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
1.008         (0.724)	Results	83
Normal breast tissue 20:4 n-6: 19 participants	Results	84
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
2.342         (1.445)	Results	85
Normal breast tissue 20:3 n-3: 19 participants	Results	86
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.038         (0.085)	Results	87
Normal breast tissue 20:5 n-3: 19 participants	Results	88
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.034         (0.147)	Results	89
Normal breast tissue 22:6 n-3: 19 participants	Results	90
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
0.061         (0.264)	Results	91
Normal breast tissue n-3: 19 participants	Results	92
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.64         (2.24)	Results	93
Normal breast tissue n-6: 19 participants	Results	94
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
3.413         (1.962)	Results	95
Normal breast tissue n3/n-6 ratio: 19 participants	Results	96
breast	UBERON:0000310	7-13
tissue	UBERON:0000479	14-20
ratio	UO:0000190	28-33
1.102         (0.438)	Results	97
Malignant breast tissue 18:2 n-6: 19 participants	Results	98
breast	UBERON:0000310	10-16
tissue	UBERON:0000479	17-23
33.735         (31.548)	Results	99
Malignant breast 18:3 n-3: 19 participants	Results	100
breast	UBERON:0000310	10-16
1.356         (1.465)	Results	101
Malignant breast 20:2 n-6: 19 participants	Results	102
breast	UBERON:0000310	10-16
0.601         (0.657)	Results	103
Malignant breast 20:4 n-6: 19 participants	Results	104
breast	UBERON:0000310	10-16
2.248         (1.744)	Results	105
Malignant breast 20:3 n-3: 19 participants	Results	106
breast	UBERON:0000310	10-16
0         (0)	Results	107
Malignant breast 20:5 n-3: 19 participants	Results	108
breast	UBERON:0000310	10-16
0         (0)	Results	109
Malignant breast 22:6 n-3: 19 participants	Results	110
breast	UBERON:0000310	10-16
0         (0)	Results	111
Malignant breast n-3: 19 participants	Results	112
breast	UBERON:0000310	10-16
1.357         (1.466)	Results	113
Malignant breast n-6: 19 participants	Results	114
breast	UBERON:0000310	10-16
36.586         (32.856)	Results	115
Malignant breast n-3/n-6 ratio: 19 participants	Results	116
breast	UBERON:0000310	10-16
ratio	UO:0000190	25-30
0.032         (0.016)	Results	117
Differences in PUFA level 18:2 n-6: 19 participants	Results	118
-39.027         (38.697)	Results	119
Differences in PUFA level 18:3 n-3: 19 participants	Results	120
-2.149         (1.935)	Results	121
Differences in PUFA level 20:2 n-6: 19 participants	Results	122
-0.407         (0.514)	Results	123
Differences in PUFA level 20:4 n-6: 19 participants	Results	124
-0.094         (1.589)	Results	125
Differences in PUFA level 20:3 n-3: 19 participants	Results	126
-0.038         (0.085)	Results	127
Differences in PUFA level 20:5 n-3: 19 participants	Results	128
-0.034         (0.147)	Results	129
Differences in PUFA level 22:6 n-3: 19 participants	Results	130
-0.061         (0.264)	Results	131
Difference in PUFA level n-3: 19 participants	Results	132
-2.282         (2.127)	Results	133
Difference in PUFA level in n-6: 19 participants	Results	134
33.173         (31.836)	Results	135
Difference in n-3/n-6 ratio: 19 participants	Results	136
ratio	UO:0000190	22-27
-1.07         (0.438)	Results	137
Adverse Events 1:	Adverse Events	0
Total: 0/28 (0.00%)	Adverse Events	1
Adverse Events 2:	Adverse Events	2
Total:	Adverse Events	3
